Hans J. Woerle

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes

Julio Rosenstock, Steven E. Kahn, Odd Erik Johansen et al. · JAMA · 2019 · 606 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

Ilkka Tikkanen, Kirsi Narko, Cordula Zeller et al. · Diabetes Care · 2014 · 462 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin

Ralph A. DeFronzo, Andrew Lewin, Sanjay Patel et al. · Diabetes Care · 2015 · 293 citations

Medicine, Pharmacology, Pharmacotherapy +14

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin

David Z.I. Cherney, Mark E. Cooper, Ilkka Tikkanen et al. · Kidney International · 2017 · 245 citations · Full text

Medicine, Nephrology, Pharmacology +11